Products - Pangea Biomed

ENLIGHT-Lens

AI-enabled Precision Drug Development

ENLIGHT-Lens brings ENLIGHT’s tumor intelligence to the aid of pharma/biotech drug development. Some of its applications are:

Novel drug target identification Genes which are at the hub of rich interaction networks (vulnerability maps) can be identified as attractive potential drug targets.
Optimal combination therapy search For a given new drug, Pangea finds the optimal partner drug for combination therapy by analyzing synergistic drug effects.
Biomarker-guided clinical trial design ENLIGHT’s precise biomarkers can guide clinical trials with optimized target population choice, including target population expansion and opening up trials in new cancer indications.
Drug lifecycle management Failed trial salvaging and label expansion by identification of patient subpopulations enriched with responders that are not yet covered by existing approvals.

ENLIGHT-NGS

RNA-based Drug Matching Analysis Nomination

ENLIGHT-NGS is an extensively validated treatment matching test driven by deep transcriptomic analysis

Based on sequencing derived from standard FFPE (Formalin Fixed, Paraffin Embedded) pathology samples, ENLIGHT-NGS delivers an actionable report helping physicians to make informed treatment decisions. ENLIGHT-NGS screens dozens of treatment options, assigning each an ENLIGHT Matching Score, and presenting the results in an intuitive, easy-to-understand report, delivering concrete actionable insights to the oncologist. ENLIGHT-matched drugs are categorized according to the level of evidence supporting their match, aiding healthcare professionals to find the best treatment for each patient. ENLIGHT-NGS tests are commercially available in several countries, and expanding to additional ones. Contact us to learn more.

ENLIGHT-DP

Treatment Matching Analysis Directly from H&E Slides

ENLIGHT-DP is a ground-breaking solution for response insights directly from H&E slides

DeepPT, Pangea's novel digital pathology (DP) deep learning platform, combined with the power of ENLIGHT to screen dozens of treatment options, generates results and insights directly from standard H&E-stained pathology slides. ENLIGHT-DP computes ENLIGHT Matching Scores for dozens of drugs, delivering actionable insights about patients’ treatment options without the need to wait for NGS results. ENLIGHT-DP tests will become commercially available in 2025.